Restricting eligibility for clinical trial participation to only patients with wild-type KRAS (wtKRAS) CRC as opposed to mutated KRAS (mutKRAS) CRC has been a crucial step in optimizing the use of EGFR targeting mAbs. The gene discussed is EGFR; the disease is colorectal carcinoma.